Eurofins Scientific earnings calendar, shares tracked against global peers

By Julia Schmitt, Sector & Peer Group desk. Reviewed prior to publication on 2026-06-26, 15:01.

Eurofins Scientific SE (FR0014000MR3) enters the current reporting period with a full earnings calendar and an established role in global laboratory testing. The stock, listed in Paris and followed by international investors alongside peers such as Thermo Fisher Scientific in the S&P 500, faces upcoming quarterly updates that will test consensus expectations from covering analysts.MarketScreener consensus data on Eurofins Scientific

What analysts currently expect

For Eurofins Scientific, consensus data collected on platforms such as MarketScreener show a broad analyst coverage with mixed ratings between Buy, Hold and occasional Sell recommendations, each paired with concrete 12-month price targets and earnings-per-share forecasts for the next reporting periods.Analyst consensus overview for Eurofins Scientific These estimates typically include revenue expectations in the multi-billion-euro range and operating margin assumptions that reflect the company’s diversified testing portfolio across food, pharmaceutical, and environmental segments.

Analyst models for Eurofins Scientific often benchmark the group against international peers such as Thermo Fisher Scientific, which trades in the S&P 500 and reports annual revenues above 40 billion US dollars according to US filings.Thermo Fisher investor relations data This peer comparison helps frame expectations for Eurofins’ scale, margin profile and capital allocation, including investments in new laboratories and acquisitions that have historically contributed to growth.

The upcoming earnings schedule

Eurofins Scientific’s investor relations calendar typically lists quarterly and half-year reporting dates, with detailed timing, format of presentations and conference calls, and access information for investors and analysts through its website.Eurofins Scientific financial calendar These events are key checkpoints for verifying whether the company’s actual revenue, EBITDA and net profit align with or deviate from consensus expectations set ahead of publication.

In the broader European context, Eurofins Scientific’s shares are part of a healthcare and laboratory services segment that includes other listed testing and diagnostics firms. Sector reports from houses such as UBS or Deutsche Bank frequently highlight trends in diagnostic volumes, regulatory developments and pricing dynamics, which serve as a backdrop for interpreting Eurofins’ forthcoming numbers and guidance updates.UBS sector research portal

The business behind the testing stock

Eurofins Scientific generates revenue primarily through laboratory testing and analytical services across several core verticals, including food safety, pharmaceutical and biotechnology quality control, and environmental analysis. In food testing, the company offers microbiological and chemical analyses to ensure products meet regulatory and safety standards in Europe, North America and other regions.

In pharmaceutical and biotechnology testing, Eurofins Scientific provides bioanalytical services for clinical trials, method development, and validation, supporting drug development programs for large and mid-sized pharma companies. Environmental laboratories under the Eurofins umbrella handle water, soil and air analyses, helping industrial clients and municipalities comply with emission and contamination regulations.

Where the Eurofins shares trade today

The Eurofins Scientific shares (FR0014000MR3) trade on Euronext Paris, with the latest verifiable price quoted on the Paris exchange in euros as of 2026-06-26, 13:00. On that date and time, the shares were last seen at around 77.44 US dollars on the ERFSF ticker in US over-the-counter trading, which corresponds to a euro-equivalent quotation when converted.ERFSF quote overview for Eurofins Scientific

Disclaimer: This article is for informational purposes only and does not constitute investment advice or a recommendation to buy or sell securities. Figures and dates are based on publicly available sources believed to be reliable at the time of publication, without any guarantee of completeness or accuracy.